Skip to main content

BCRX

Stock
Health Care
Biotechnology

Performance overview

BCRX Price
Price Chart

Forward-looking statistics

Beta
0.96
Risk
55.62%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Company info

SectorHealth Care
IndustryBiotechnology
Employees513
Market cap$1.3B

Fundamentals

Enterprise value$2.4B
Revenue$503.5M
Revenue per employee
Profit margin-10.62%
Debt to equity-1.84

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.26
Dividend per share
Revenue per share$2.43
Avg trading volume (30 day)$32M
Avg trading volume (10 day)$34M
Put-call ratio

Macro factor sensitivity

Growth-4.0
Credit+9.6
Liquidity+1.9
Inflation-7.1
Commodities-2.7
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-223.50
Price to sales3.72
P/E Ratio-223.50
Enterprise Value to Revenue4.79
Price to book-4.13

Upcoming events

Next earnings dayFebruary 24, 2025
Next dividend day
Ex. dividend dayJune 11, 2014

News

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Investment Research (July 7, 2025)
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility

INSW, ASR, BCRX, ASC and RRGB top the list of highly efficient stocks poised for gains amid market volatility.

Zacks Investment Research (June 25, 2025)
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.

Benzinga (May 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free